Literature DB >> 24411613

Dosimetric implications of an injection of hyaluronic acid for preserving the rectal wall in prostate stereotactic body radiation therapy.

Olivier Chapet1, Corina Udrescu2, Ronan Tanguy3, Alain Ruffion4, Pascal Fenoglietto5, Marie-Pierre Sotton6, Marian Devonec4, Marc Colombel7, Patrice Jalade6, David Azria5.   

Abstract

PURPOSE: This study assessed the contribution of ahyaluronic acid (HA) injection between the rectum and the prostate to reducing the dose to the rectal wall in stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: As part of a phase 2 study of hypofractionated radiation therapy (62 Gy in 20 fractions), the patients received a transperineal injection of 10 cc HA between the rectum and the prostate. A dosimetric computed tomographic (CT) scan was systematically performed before (CT1) and after (CT2) the injection. Two 9-beam intensity modulated radiation therapy-SBRT plans were optimized for the first 10 patients on both CTs according to 2 dosage levels: 5 × 6.5 Gy (PlanA) and 5 × 8.5 Gy (PlanB). Rectal wall parameters were compared with a dose-volume histogram, and the prostate-rectum separation was measured at 7 levels of the prostate on the center line of the organ.
RESULTS: For both plans, the average volume of the rectal wall receiving the 90% isodose line (V90%) was reduced up to 90% after injection. There was no significant difference (P=.32) between doses received by the rectal wall on CT1 and CT2 at the base of the prostate. This variation became significant from the median plane to the apex of the prostate (P=.002). No significant differences were found between PlanA without HA and PlanB with HA for each level of the prostate (P=.77, at the isocenter of the prostate).
CONCLUSIONS: HA injection significantly reduced the dose to the rectal wall and allowed a dose escalation from 6.5 Gy to 8.5 Gy without increasing the dose to the rectum. A phase 2 study is under way in our department to assess the rate of acute and late rectal toxicities when SBRT (5 × 8.5 Gy) is combined with an injection of HA.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24411613     DOI: 10.1016/j.ijrobp.2013.10.039

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?

Authors:  Stefano Arcangeli; Linda Agolli; Vittorio Donato
Journal:  Rep Pract Oncol Radiother       Date:  2014-09-10

2.  PEG spacer gel and adaptive planning vs single plan in external prostate radiotherapy--clinical dosimetry evaluation.

Authors:  Vesa-Pekka Heikkilä
Journal:  Br J Radiol       Date:  2015-09-15       Impact factor: 3.039

3.  Effect of hyaluronic acid on radiotherapy-induced mucocutaneous side effects: a meta-analysis of randomized controlled trials.

Authors:  Ruo-Zhu Tai; El-Wui Loh; Jo-Ting Tsai; Ka-Wai Tam
Journal:  Support Care Cancer       Date:  2022-02-12       Impact factor: 3.603

Review 4.  ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.

Authors:  Nicholas G Zaorsky; Timothy N Showalter; Gary A Ezzell; Paul L Nguyen; Dean G Assimos; Anthony V D'Amico; Alexander R Gottschalk; Gary S Gustafson; Sameer R Keole; Stanley L Liauw; Shane Lloyd; Patrick W McLaughlin; Benjamin Movsas; Bradley R Prestidge; Al V Taira; Neha Vapiwala; Brian J Davis
Journal:  Adv Radiat Oncol       Date:  2016-10-20

5.  Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?

Authors:  Angèle Dubouloz; Michel Rouzaud; Lev Tsvang; Wilko Verbakel; Mikko Björkqvist; Nadine Linthout; Joana Lencart; Juan María Pérez-Moreno; Zeynep Ozen; Lluís Escude; Thomas Zilli; Raymond Miralbell
Journal:  Radiat Oncol       Date:  2018-06-19       Impact factor: 3.481

6.  Dosimetric feasibility of stereotactic irradiation of primary prostate cancer at 5x9 Gy with a method of urethral sparing.

Authors:  Salim Benhmida; Amandine Beneux; Corina Udrescu; Olivier Rouviere; Samy Horn; Ciprian Enachescu; Ariane Lapierre; Olivier Chapet
Journal:  Br J Radiol       Date:  2021-07-20       Impact factor: 3.039

7.  Prostate hypofractionated radiotherapy (62Gy at 3.1Gy per fraction) with injection of hyaluronic acid: final results of the RPAH1 study.

Authors:  Olivier Chapet; Corina Udrescu; Sylvie Bin; Evelyne Decullier; Pascal Fenoglietto; Amandine Beneux; Bruno Segui; Ciprian Enachescu; Sonya Gaudioz; Alain Ruffion; David Azria
Journal:  Br J Radiol       Date:  2021-08-01       Impact factor: 3.629

8.  BioPro-RCMI-1505 trial: multicenter study evaluating the use of a biodegradable balloon for the treatment of intermediate risk prostate cancer by intensity modulated radiotherapy; study protocol.

Authors:  David Pasquier; Emilie Bogart; François Bonodeau; Thomas Lacornerie; Eric Lartigau; Igor Latorzeff
Journal:  BMC Cancer       Date:  2018-05-16       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.